SHARE

Report Highlights

Latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Pipeline Review, H1 2018, provides an overview of the Pancreatic Cancer pipeline landscape. Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pancreatic Cancer , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 1, 1, 16, 120, 121, 2, 8, 273, 36 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 20, 9, 52 and 6 molecules, respectively.

Pancreatic Cancer pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned in Pancreatic Cancer are: 3-V Biosciences Inc, 4P-Pharma SAS, 4SC AG, AB Science SA, AbbVie Inc, AbGenomics International Inc, Ability Pharmaceuticals SL, Aclaris Therapeutics Inc, Actuate Therapeutics Inc, Adamed Sp z oo, Aduro BioTech Inc, Advanced Cancer Therapeutics LLC, Advantagene Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alissa Pharma, Allinky Biopharma, Almac Discovery Ltd, Altor BioScience Corp, Ambrx Inc, amcure GmbH, American Gene Technologies International Inc, Amgen Inc, Anavex Life Sciences Corp, Andarix Pharmaceuticals Inc, ANP Technologies Inc, AntiCancer Inc, APEIRON Biologics AG, Apexigen Inc, Aphios Corp, APIM Therapeutics AS, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc, Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, AVEO Pharmaceuticals Inc, Axcentua Pharmaceuticals AB, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Berg LLC, BerGenBio ASA, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, BioLineRx Ltd, BioMoti Ltd, Biomunex Pharmaceuticals, Bionomics Ltd, BioNTech AG, Biouniversa srl, BLR Bio LLC, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Co, Calithera Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Cantargia AB, Cantex Pharmaceuticals Inc, CARsgen Therapeutics Ltd, Cascadian Therapeutics Inc, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Celleron Therapeutics Ltd, Cellular Biomedicine Group Inc, Celprogen Inc, Celyad SA, Centrose LLC, Ceronco Biosciences, Chem-Master International Inc, ChemoCentryx Inc, Chugai Pharmaceutical Co Ltd, Clovis Oncology Inc, COARE Biotechnology Inc, Codiak BioSciences Inc, Concordia International Corp, Critical Outcome Technologies Inc, CrystalGenomics Inc, CTI BioPharma Corp, Cyclacel Pharmaceuticals Inc, CytImmune Sciences Inc, Cytori Therapeutics Inc, CyTuVax BV, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, DEKK-TEC Inc, Denceptor Therapeutics Ltd, Diffusion Pharmaceuticals Inc, Eisai Co Ltd, Eleison Pharmaceuticals LLC, Eli Lilly and Co, Endor Nanotechnologies SL, Ensemble Therapeutics Corp, Ensol Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Etubics Corp, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faron Pharmaceuticals Oy, Felicitex Therapeutics Inc, FibroGen Inc, Formosa Laboratories Inc, Forty Seven Inc, Fountain Biopharma Inc, Fujifilm Holdings Corporation, Fusion Antibodies Ltd, Galena Biopharma Inc, Galera Therapeutics Inc, GamaMabs Pharma SA, Geistlich Pharma AG, Genelux Corp, Genentech Inc, Genisphere LLC, Genoscience Pharma, Gilead Sciences Inc, GlaxoSmithKline Plc, GlycoMimetics Inc, Glycotope GmbH, Golden Biotechnology Corp, GW Pharmaceuticals Plc, Halozyme Therapeutics Inc, Heidelberg Pharma AG, Helix BioPharma Corp, Hemispherx Biopharma Inc, Horizon Pharma Plc, iCeutica Inc, Idera Pharmaceuticals Inc, Igenica Biotherapeutics Inc, Ignyta Inc, Immodulon Therapeutics Ltd, Immune System Key Ltd, Immunitor Inc, Immunomedics Inc, Immunotope Inc, Immunovo BV, Immupharma Plc, Incyte Corp, Inflection Biosciences Ltd, Innopharmax Inc, Innovation Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Intezyne Technologies Inc, Inventiva, InvivoGen Therapeutics, Io Therapeutics Inc, Iovance Biotherapeutics Inc, Ipsen SA, ISU ABXIS Co Ltd, Jasco Pharmaceuticals LLC, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kalyra Pharmaceuticals Inc, Kancera AB, Karcinolys SAS, Karyopharm Therapeutics Inc, Kazia Therapeutics Ltd, Keystone Nano Inc, Komipharm International Co Ltd, Kringle Pharma Inc, Kura Oncology Inc, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Lidds AB, LIfT BioSciences Ltd, Lixte Biotechnology Holdings Inc, Loxo Oncology Inc, Lymphocyte Activation Technologies SA, MabVax Therapeutics Holdings Inc, MacroGenics Inc, Madrigal Pharmaceuticals Inc., MaxiVAX SA, Meabco AS, Mebiopharm Co Ltd, MediaPharma SRL, Medicenna Therapeutics Corp, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Millennium Pharmaceuticals Inc, Moderna Therapeutics Inc, Molecular Partners AG, Molecular Templates Inc, Moleculin Biotech Inc, MolMed SpA, Monopar Therapeutics LLC, Morphotek Inc, NanoCarrier Co Ltd, NanoVector Inc, NantKwest Inc, Nascent Biotech Inc, Natco Pharma Ltd, NatureWise Biotech & Medicals Corp, NBE-Therapeutics AG, Nerviano Medical Sciences Srl, NewLink Genetics Corp, NormOxys Inc, Novartis AG, Noxxon Pharma AG, NuCana Plc, OBI Pharma Inc, Omeros Corp, Oncodesign SA, Oncolytics Biotech Inc, Oncomatryx Biopharma SL, OncoMed Pharmaceuticals Inc, OncoTherapy Science Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Opsona Therapeutics Ltd, Optimum Therapeutics LLC, Orega Biotech SAS, Oribase Pharma, Oryx GmbH & Co KG, OSE Immunotherapeutics, Oxford BioTherapeutics Ltd, Patrys Ltd, Pfizer Inc, Pharma Two B Ltd, PharmAbcine Inc, PharmaCyte Biotech Inc, Pharmedartis GmbH, Phoenix Biotechnology Inc, Plexxikon Inc, Polaris Pharmaceuticals Inc, Precision Biologics Inc, Prescient Therapeutics Ltd, Propanc Biopharma Inc, Provectus Biopharmaceuticals Inc, Puretech Health plc, Quest PharmaTech Inc, Quimatryx SL, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Redx Pharma Plc, Rexahn Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Sagetis Biotech SL, Samumed LLC, Samyang Holdings Corp, Sanofi, Sareum Holdings Plc, SATT North SAS, Scancell Holdings Plc, Selecta Biosciences Inc, Siamab Therapeutics Inc, Sierra Oncology Inc, SignPath Pharma Inc, SilaGene Inc, Silenseed Ltd, Sillajen Biotherapeutics, Sino Biopharmaceutical Ltd, Soricimed Biopharma Inc, Sorrento Therapeutics Inc, Spring Bank Pharmaceuticals Inc, Stelic Institute & Co Inc, Strongbridge Biopharma plc, Sumitomo Dainippon Pharma Co Ltd, Sun BioPharma Inc, Sun Pharma Advanced Research Company Ltd, Sunshine Biopharma Inc, Swedish Orphan Biovitrum AB, Symphogen A/S, SynCore Biotechnology Co Ltd, Syndax Pharmaceuticals Inc, Synergys Biotherapeutics Inc, Synovo GmbH, SyntheX Inc, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takara Bio Inc, Takeda Pharmaceutical Co Ltd, Takis Srl, Targovax ASA, Tarveda Therapeutics Inc, tella Inc, Tiltan Pharma Ltd, Tiziana Life Sciences Plc, Tocagen Inc, Transcriptogen Ltd, Transgene SA, TVAX Biomedical Inc, Tyg Oncology Ltd, Tyme Technologies Inc, Tyrogenex Inc, UbiVac LLC, ValiRx Plc, VasGene Therapeutics Inc, Vault Pharma Inc, Vaxeal Holding SA, Vaximm AG, Vaxon Biotech, VCN Biosciences SL, Vect-Horus SAS, Verastem Inc, VG Life Sciences Inc, Vicus Therapeutics LLC, ViiV Healthcare UK Ltd, Viralytics Ltd, Virobay Inc, ViroStatics srl, Zeria Pharmaceutical Co Ltd.

Request for a Sample Copy of this Research Report at: https://www.marketinsightsreports.com/reports/07055853/pancreatic-cancer-pipeline-review-h1-2017/inquiry?source=apexnews&Mode=01

Scope:

  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer.
    2. The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
    3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    5. The pipeline guide reviews key companies involved in Pancreatic Cancer therapeutics and enlists all their major and minor projects.
    6. The pipeline guide evaluates Pancreatic Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    8. The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer

Browse full Report at: https://www.marketinsightsreports.com/reports/07055853/pancreatic-cancer-pipeline-review-h1-2017?source=apexnews&Mode=01

Report Coverage:

The objective of updating report coverage is to ensure that it represents the most up to date vision of the industry possible. The report covers all the pharmaceutical/biopharmaceutical products under development across the globe. The scope of the pipeline products coverage aims at setting up the boundaries of the project. It comprises all the therapeutic Products that are in the course of development, however, if a drug is solely used for research purpose, where the Intention for its further development as a drug is not clear or the strategy for commercialization is not known, the drug is not included in the report. Our aims to cover major news events and deals in the pharmaceutical Industry, updated on daily basis. The coverage is further streamlined and strengthened with additional inputs from our Expert Panel.

Important Points Covered In Table of Content are:

Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.

List of Tables Mentioned are:

1) Number of Products under Development for Pancreatic Cancer, H1 2018, 2) Number of Products under Development by Companies, H1 2018, 3) Number of Products under Development by Universities/Institutes, H1 2018, 4) Products under Development by Companies, H1 2018, 5) Products under Development by Universities/Institutes, H1 2018, 6) Number of Products by Stage and Target, H1 2018, 7) Number of Products by Stage and Mechanism of Action, H1 2018, 8) Number of Products by Stage and Route of Administration, H1 2018, 9) Number of Products by Stage and Molecule Type, H1 2018